We estimate that the President, CEO of BIOMARIN PHARMACEUTICAL INC ($BMRN), Alexander Hardy, received a compensation of $21,927,563 in 2025. This is an increase of 32.26% from an estimated $14,853,605 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on April 21, 2026. Note that parsing errors may occur.
You can track $BMRN on Quiver Quantitative's $BMRN stock dashboard.
$BMRN Stock Insider Trading Activity
$BMRN Stock insiders have traded $BMRN stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BMRN stock by insiders over the last 6 months:
- GEORGE ERIC DAVIS (EVP, Chief Legal Officer) sold 26,061 shares for an estimated $1,599,102
- CHARLES GREG GUYER (EVP, Chief Technical Officer) sold 16,486 shares for an estimated $996,743
- GREGORY R FRIBERG (EVP, Chief R&D Officer) sold 6,326 shares for an estimated $381,937
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BMRN Stock Hedge Fund Activity
We have seen 259 institutional investors add shares of $BMRN Stock stock to their portfolio, and 339 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORGES BANK added 5,487,201 shares (+268.5%) to their portfolio in Q4 2025, for an estimated $326,104,355
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,657,967 shares (-85.1%) from their portfolio in Q4 2025, for an estimated $217,392,978
- BLACKROCK, INC. removed 2,910,942 shares (-13.2%) from their portfolio in Q4 2025, for an estimated $172,997,283
- VIKING GLOBAL INVESTORS LP removed 2,285,243 shares (-27.5%) from their portfolio in Q4 2025, for an estimated $135,811,991
- DEEP TRACK CAPITAL, LP added 2,275,144 shares (+9153.3%) to their portfolio in Q4 2025, for an estimated $135,211,807
- VESTAL POINT CAPITAL, LP added 2,170,000 shares (+261.4%) to their portfolio in Q4 2025, for an estimated $128,963,100
- FMR LLC added 1,444,256 shares (+367.7%) to their portfolio in Q4 2025, for an estimated $85,832,134
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BMRN Stock Analyst Ratings
Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 01/20/2026
- Bernstein issued a "Outperform" rating on 11/03/2025
- Morgan Stanley issued a "Overweight" rating on 10/28/2025
- Barclays issued a "Overweight" rating on 10/28/2025
- Truist Securities issued a "Buy" rating on 10/28/2025
- Wells Fargo issued a "Overweight" rating on 10/28/2025
To track analyst ratings and price targets for $BMRN Stock, check out Quiver Quantitative's $BMRN forecast page.
$BMRN Stock Price Targets
Multiple analysts have issued price targets for $BMRN recently. We have seen 14 analysts offer price targets for $BMRN in the last 6 months, with a median target of $85.5.
Here are some recent targets:
- Geoff Meacham from B of A Securities set a target price of $85.0 on 03/11/2026
- Eliana Merle from Barclays set a target price of $105.0 on 03/04/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $55.0 on 03/02/2026
- Whitney Ijem from Canaccord Genuity set a target price of $104.0 on 02/26/2026
- Debjit Chattopadhyay from Guggenheim set a target price of $86.0 on 02/25/2026
- William Pickering from Bernstein set a target price of $94.0 on 02/25/2026
- Leland Gershell from Oppenheimer set a target price of $95.0 on 02/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
